Alkis J Psaltis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11641797/publications.pdf

Version: 2024-02-01

257450 330143 2,972 38 24 37 h-index citations g-index papers 40 40 40 2310 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. International Forum of Allergy and Rhinology, 2016, 6, S22-209.	2.8	443
2	International consensus statement on allergy and rhinology: rhinosinusitis 2021. International Forum of Allergy and Rhinology, 2021, 11, 213-739.	2.8	398
3	过æ•和鼻科å¦å،½é™…å…±è⁻†å£°æ~Ž∶鼻窦ç,Ž. International Forum of Allergy and Rhinology, 2016, 6, 9	52 2. 8	339
4	The Effect of Bacterial Biofilms on Post-sinus Surgical Outcomes. American Journal of Rhinology & Allergy, 2008, 22, 1-6.	2.2	182
5	Confocal Scanning Laser Microscopy Evidence of Biofilms in Patients With Chronic Rhinosinusitis. Laryngoscope, 2007, 117, 1302-1306.	2.0	169
6	Modification of the lundâ€kennedy endoscopic scoring system improves its reliability and correlation with patientâ€reported outcome measures. Laryngoscope, 2014, 124, 2216-2223.	2.0	169
7	Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis Patients. Frontiers in Cellular and Infection Microbiology, 2017, 7, 418.	3.9	132
8	The Impact of Biofilms on Outcomes after Endoscopic Sinus Surgery. American Journal of Rhinology and Allergy, 2010, 24, 169-174.	2.0	123
9	In Vitro Activity of Mupirocin on Clinical Isolates of <i>Staphylococcus aureus</i> and its Potential Implications in Chronic Rhinosinusitis. Laryngoscope, 2008, 118, 535-540.	2.0	90
10	A Sheep Model for the Study of Biofilms in Rhinosinusitis. American Journal of Rhinology & Allergy, 2007, 21, 339-345.	2.2	82
11	Longâ€term Sinonasal Outcomes of Aspirin Desensitization in Aspirin Exacerbated Respiratory Disease. Otolaryngology - Head and Neck Surgery, 2014, 151, 575-581.	1.9	80
12	Reduced Levels of Lactoferrin in Biofilm-Associated Chronic Rhinosinusitis. Laryngoscope, 2008, 118, 895-901.	2.0	67
13	Nasal Mucosa Expression of Lactoferrin in Patients With Chronic Rhinosinusitis. Laryngoscope, 2007, 117, 2030-2035.	2.0	64
14	Outcomes of modified endoscopic Lothrop in aspirinâ€exacerbated respiratory disease with nasal polyposis. International Forum of Allergy and Rhinology, 2016, 6, 820-825.	2.8	62
15	The international sinonasal microbiome study: A multicentre, multinational characterization of sinonasal bacterial ecology. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2037-2049.	5.7	55
16	Therapy of Sinonasal Microbiome in CRS: A Critical Approach. Current Allergy and Asthma Reports, 2017, 17, 59.	5.3	50
17	Targeted imaging modality selection for bacterial biofilms in chronic rhinosinusitis. Laryngoscope, 2010, 120, 427-431.	2.0	47
18	Longâ€ŧerm outcomes of endoscopic maxillary megaâ€antrostomy for refractory chronic maxillary sinusitis. International Forum of Allergy and Rhinology, 2015, 5, 60-65.	2.8	36

#	Article	IF	Citations
19	Next Generation Sequencing and the Microbiome of Chronic Rhinosinusitis. Annals of Otology, Rhinology and Laryngology, 2016, 125, 613-621.	1.1	32
20	The Association Between Disease Severity and Microbiome in Chronic Rhinosinusitis. Laryngoscope, 2019, 129, 1265-1273.	2.0	32
21	Medical therapy vs surgery for recurrent acute rhinosinusitis. International Forum of Allergy and Rhinology, 2015, 5, 667-673.	2.8	31
22	Pseudomonas aeruginosa Exoprotein-Induced Barrier Disruption Correlates With Elastase Activity and Marks Chronic Rhinosinusitis Severity. Frontiers in Cellular and Infection Microbiology, 2019, 9, 38.	3.9	31
23	Innate Immunity. Otolaryngologic Clinics of North America, 2010, 43, 473-487.	1.1	30
24	Safety and efficacy of a bacteriophage cocktail in an in vivo model of Pseudomonas aeruginosa sinusitis. Translational Research, 2019, 206, 41-56.	5.0	27
25	Microbiotyping the Sinonasal Microbiome. Frontiers in Cellular and Infection Microbiology, 2020, 10, 137.	3.9	21
26	Partial resection of the middle turbinate during endoscopic sinus surgery for chronic rhinosinusitis does not lead to an increased risk of empty nose syndrome: a cohort study of a tertiary practice. International Forum of Allergy and Rhinology, 2018, 8, 959-963.	2.8	20
27	Topical Colloidal Silver for the Treatment of Recalcitrant Chronic Rhinosinusitis. Frontiers in Microbiology, 2018, 9, 720.	3.5	20
28	Manuka honey sinus irrigations in recalcitrant chronic rhinosinusitis: phase 1 randomized, singleâ€blinded, placeboâ€controlled trial. International Forum of Allergy and Rhinology, 2019, 9, 1470-1477.	2.8	20
29	Unraveling the role of the microbiome in chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 2022, 149, 1513-1521.	2.9	20
30	<i>Staphylococcus aureus</i> biofilm exoproteins are cytotoxic to human nasal epithelial barrier in chronic rhinosinusitis. International Forum of Allergy and Rhinology, 2020, 10, 871-883.	2.8	18
31	Outcomes of revision endoscopic modified Lothrop procedure. International Forum of Allergy and Rhinology, 2016, 6, 518-522.	2.8	17
32	Inhibition of <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> biofilms by quatsomes in low concentrations. Experimental Biology and Medicine, 2020, 245, 34-41.	2.4	15
33	Safety and Efficacy of Topical Chitogel- Deferiprone-Gallium Protoporphyrin in Sheep Model. Frontiers in Microbiology, 2018, 9, 917.	3.5	13
34	Comparative Viral Sampling in the Sinonasal Passages; Different Viruses at Different Sites. Frontiers in Cellular and Infection Microbiology, 2018, 8, 334.	3.9	10
35	Overcoming bacteriophage insensitivity in <i>Staphylococcus aureus</i> using clindamycin and azithromycinat subinhibitory concentrations. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3446-3458.	5.7	9
36	Staphylococcus aureus from patients with chronic rhinosinusitis show minimal genetic association between polyp and non-polyp phenotypes. BMC Ear, Nose and Throat Disorders, 2018, 18, 16.	2.6	8

ALKIS J PSALTIS

#	Article	lF	CITATIONS
37	What are the challenges in choosing pharmacotherapy for rhinosinusitis?. Expert Opinion on Pharmacotherapy, 2020, 21, 427-433.	1.8	1
38	<i>In vitro</i> safety and antiâ€bacterial efficacy assessment of acriflavine. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1917-1920.	5.7	0